<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Use of androgens and other hormones by athletes</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Use of androgens and other hormones by athletes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Use of androgens and other hormones by athletes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alvin M Matsumoto, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter Fricker, MBBS, FACSP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Some athletes use drugs to attempt to improve their performance. The focus of the general news media is on the professional athletes who are caught using hormonal drugs, most commonly, androgens, in sporting events such as the Olympic Games and major league baseball. However, the majority of individuals using these medications are recreational athletes (eg, weightlifters and bodybuilders) who use them to improve overall strength and personal appearance [<a href="#rid1">1</a>].</p><p>This topic will focus on the epidemiology, physical and adverse effects, and detection of hormones used to improve athletic performance and physical appearance. The use of nonhormonal agents and nonpharmacologic enhancement methods (such as blood transfusions) are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15454.html" rel="external">"Prohibited non-hormonal performance-enhancing drugs in sport"</a>.)</p><p class="headingAnchor" id="H364314834"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Performance-enhancing drugs</strong> – Agents used to attempt to enhance athletic performance, and in the case of weightlifters/bodybuilders, physical appearance, with a goal of appearing leaner and more muscular. Although users take these drugs to improve their performance, data supporting their efficacy are limited. (See <a class="local">'Efficacy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Doping</strong> – "Doping" refers to the use of banned substances in competitive sports.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Androgenic steroids</strong> – These (naturally occurring or synthetic) hormones increase lean body mass and decrease fat mass and are the most frequently used class of performance-enhancing drugs. The synthetic hormones differ from testosterone, as described below. The author of this topic uses the term "androgens" or "androgenic steroids" rather than "anabolic-androgenic steroids" because the anabolic effects of a steroid cannot be separated from its androgenic effects. (See <a class="local">'"Androgenic steroids"'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>World Anti-Doping Agency (WADA)</strong> – WADA is the organization that oversees anti-doping policies and determines the list of substances (and doping methods) that are banned from sports. This includes hormonal and nonhormonal drugs as well as dietary supplements.</p><p></p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The use of androgens has spread from competitive sports to leisure and fitness sports [<a href="#rid1">1-3</a>]. Bodybuilders and nonathletes use androgens as a strategy to increase muscle mass, improve performance, and enhance physical attractiveness. The frequency of this use of drugs by athletes and nonathletes has been addressed in a number of studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Use of androgenic steroids has become a serious global public health problem. In a meta-analysis of 187 studies, the overall global lifetime prevalence rate was 3.3 percent but was higher in men (6.4 percent) than women (1.6 percent) [<a href="#rid4">4</a>]. The rate was higher among recreational athletes than professional athletes (18.4 versus 13.3 percent) and varied by region (highest in the Middle East [22 percent] compared with other regions of the world [2 to 5 percent]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Androgenic steroid use is thought to be common among police officers and the military, although prevalence data are limited. In a study of the use in British soldiers, reported usage was low compared with other groups above: 4.2 percent for testosterone, 1.1 percent for other androgenic steroids, and 2 percent for growth hormone [<a href="#rid5">5</a>]. A survey of United States military personnel found that 1.4 percent of individuals reported prescription anabolic steroid use and/or misuse in the past 12 months, and 5.6 percent reported use/misuse in their lifetime [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Up to one-third of users develop dependence; most individuals who develop dependence are men [<a href="#rid7">7</a>]. It is estimated that in the United States alone, one million men have experienced androgenic steroid dependence. In one report, androgenic steroid users with dependence were more likely than those without dependence to have coexisting substance abuse and mental health disorders (heroin use, anxiety, and depression) [<a href="#rid8">8,9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 2013, the United States Centers for Disease Control and Prevention (CDC) reported that 3.2 percent of high school students had taken androgenic steroids without a doctor's prescription at least once [<a href="#rid10">10</a>]. Among students nationwide, the prevalence increased from 1991 to 2001 (from 2.7 to 5.0 percent) and then decreased between 2001 and 2013 (from 5.0 to 3.2 percent). The lifetime prevalence of use in high school males and females was 2.2 and 4.0 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although androgen use is common among teenagers [<a href="#rid10">10,11</a>], the average age of onset of use appears to be in the early 20s [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Growth hormone, like androgens, has been linked to many prominent athletes in sports such as baseball, swimming, and cycling [<a href="#rid12">12</a>]. In addition, approximately 5 percent of United States high school students report using growth hormone [<a href="#rid2">2</a>]. (See <a class="local">'Growth hormone'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of these medications is more common when there is a family or personal history of drug abuse [<a href="#rid1">1,13,14</a>].</p><p></p><p class="headingAnchor" id="H606912358"><span class="h2">Patterns of use</span><span class="headingEndMark"> — </span>As most athletes who take androgens or other agents to improve athletic performance do so surreptitiously, the pattern of use differs substantially from that of other medications/drugs:</p><p class="bulletIndent1"><span class="glyph">●</span>Users most often obtain androgens from the internet. Suppliers often provide packages containing a variety of drugs: testosterone, synthetic androgens, aromatase inhibitors, human chorionic gonadotropin (hCG), and phosphodiesterase inhibitors [<a href="#rid15">15,16</a>]. Some users will take drugs intended for veterinary purposes or obtain substances from laboratories that are not regulated by government agencies for manufacturing quality, so they may contain more or less than the stated amount.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some bodybuilding dietary supplements contain androgens, resulting in unwitting ingestion of banned substances [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some users will take more than the prescribed dose or will use medications prescribed for others.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Athletes often take these drugs in various patterns, including in escalating doses ("pyramiding") and/or combining two or more steroids ("stacking"). Often, androgen users "pyramid" their doses in cycles of 6 to 12 weeks. They start with low doses of each drug, slowly increase until the middle of the cycle, and then taper back down to zero. Androgen deficiency may occur during this interval, and users typically take other medications such as <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> citrate or hCG to attempt to help the hypothalamic-pituitary-gonadal axis recover more quickly, but there is no evidence that they do so [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Users may attempt to counter a side effect of one medication with another medication. As examples, most <strong>stacks</strong> will include both androgens and other drugs such as growth hormone for additional anabolic effect, hCG to counteract the reduction in testicular size resulting from high-dose androgen use, an aromatase inhibitor to counteract gynecomastia, a 5-alpha reductase inhibitor to prevent balding and acne that occur with exogenous androgens, and diuretics to promote water loss. (See <a class="local">'Use of hCG'</a> below and <a class="local">'Estrogen blockade'</a> below and  <a class="medical medical_review" href="/z/d/html/15454.html" rel="external">"Prohibited non-hormonal performance-enhancing drugs in sport", section on 'Agents used to prevent detection of banned substances'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Athletes discontinue the medications periodically to avoid side effects and detection just before a competition. (See <a class="local">'Avoiding detection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rather than asking a clinician, users typically seek information about these drugs from other athletes, trainers, magazines, underground publications, and the internet.</p><p></p><p class="headingAnchor" id="H606912732"><span class="h2">Banned drugs</span><span class="headingEndMark"> — </span>In the past decade, the list of drugs banned by the World Anti-Doping Agency (WADA) has grown to over 100 [<a href="#rid18">18</a>]. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.wada-ama.org%2Fen%2Fprohibited-list&amp;token=LyMsj877A%2Fv8KGeom5Z8pa8h4V2YuwJyT2l%2B3U%2FQDAj%2BtR7kQKw%2Bf49nhaBQ7ZmyyuOkg3HeYe8jR0OMPa0VfA%3D%3D&amp;TOPIC_ID=7475" target="_blank">2017 WADA list</a> includes androgens, "peptide hormones, growth factors and related substances," hormone antagonists and modulators, diuretics and other masking agents, stimulants, narcotics, cannabinoids, alcohol, glucocorticoids, beta-agonists, and beta blockers. It also includes different prohibited methods of enhancement including oxygen transfer, chemical and physical manipulation, and gene doping. (See  <a class="medical medical_review" href="/z/d/html/15454.html" rel="external">"Prohibited non-hormonal performance-enhancing drugs in sport"</a>.)</p><p>Clinicians caring for competitive athletes should be aware of doping regulations as some banned drugs may be taken for medical purposes (eg, beta blockers, diuretics, 5-alpha-reductase inhibitors). Although athletes are responsible for informing clinicians that they are subject to doping restrictions, they may not realize that they are taking a substance that is prohibited. Clinicians should consider reviewing drug and/or supplement use to determine if an athlete is taking a banned substance.</p><p>In some cases (such as an athlete under the jurisdiction of a sport's governing body and subject to dope testing), clinicians may be asked to provide documentation for therapeutic use exemption to use banned substances for medical conditions, eg, testosterone for hypogonadism or growth hormone for growth hormone deficiency. (See <a class="local">'Therapeutic use exemption'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">ANDROGENS</span></p><p class="headingAnchor" id="H5"><span class="h2">Types of androgens</span><span class="headingEndMark"> — </span>Virtually all androgens produced for human or veterinary purposes have been taken by athletes  (<a class="graphic graphic_figure graphicRef53955" href="/z/d/graphic/53955.html" rel="external">figure 1</a>). These include testosterone esters, which are usually taken by injection; the 17-alpha-alkylated androgens, which are usually taken orally; and androgen precursors. Most commonly used are testosterone, trenbolone, and boldenone (a veterinary steroid) [<a href="#rid7">7</a>]. Among elite athletes, the most commonly detected drugs are testosterone, stanozolol, and nandrolone.</p><p class="headingAnchor" id="H606909518"><span class="h3">Exogenous testosterone</span><span class="headingEndMark"> — </span>The testosterone esters include the enanthate and cypionate, which are also used for hormone replacement. Testosterone preparations for clinical use are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Choice of testosterone regimen'</a>.)</p><p class="headingAnchor" id="H606909511"><span class="h3">"Androgenic steroids"</span><span class="headingEndMark"> — </span>"Androgenic steroids," also referred to as "anabolic-androgenic steroids," are synthetic steroidal androgens: oral 17-alpha-alkylated androgens (such as stanozolol) or parenteral 19-nortestosterone derivatives (such as nandrolone). They were originally developed to have a greater anabolic to androgenic effect than testosterone [<a href="#rid19">19</a>]. The author and editors of this topic use the term "androgens" or "androgenic steroids" rather than "anabolic-androgenic steroids" for these compounds because the anabolic effects of a steroid cannot be separated from its androgenic effects.</p><p class="headingAnchor" id="H7"><span class="h3">Androgen precursors</span><span class="headingEndMark"> — </span>The androgen precursors include androstenedione and dehydroepiandrosterone (DHEA).</p><p class="bulletIndent1"><span class="glyph">●</span>Androstenedione is widely used and promoted in bodybuilding magazines. Until 2004, products containing androstenedione ("andro") were available as over-the-counter nutritional supplements. However, in October 2004, the Anabolic Steroid Control Act classified androstenedione (and 17 other steroids) as controlled substances with significant health risks. As of January 2005, these substances may not be sold without a prescription [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Androstenedione does not appear to have an anabolic effect like testosterone, and it has little, if any, effect on increasing the serum concentration of testosterone [<a href="#rid21">21-23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DHEA is also available as a "nutritional supplement" and is widely touted in body-building magazines as an agent that increases muscle strength. It is not androgenic itself but is converted to testosterone and raises serum concentrations in women but not men [<a href="#rid24">24-26</a>].</p><p></p><p class="headingAnchor" id="H606910564"><span class="h3">SARMs</span><span class="headingEndMark"> — </span>Selective androgen receptor modulators (SARMs) are nonsteroidal, orally active molecules developed to bind better to androgen receptors in certain tissues, such as muscle and bone, than to those in genital tissue, with the goal of improving muscle weakness, osteoporosis, and other conditions with less risk of worsening prostate diseases in men or causing virilization in women. Although none of these compounds have been approved for use in humans in any country, they are now widely available via the internet [<a href="#rid27">27,28</a>] and the SARM andarine was detected in a urine sample from an athlete [<a href="#rid29">29</a>].</p><p>Like many dietary supplements sold on the internet, the labeling for SARM products marketed as performance-enhancing drugs is misleading. In a study of 44 SARM products purchased from the internet and analyzed using procedures approved by World Anti-Doping Agency (WADA), only 18 had accurate labeling (eg, they contained the correct SARM [andarine, ostarine, or LGD-4033], and dosage) [<a href="#rid30">30</a>]. Four products contained no active compounds at all, and the remainder (22; 50 percent) were inaccurately labeled (the wrong SARM, an inaccurate dose of the SARM listed, and/or at least one additional unapproved drug or substance [eg, growth hormone secretagogues, "androgenic steroids"]). (See  <a class="medical medical_review" href="/z/d/html/1392.html" rel="external">"Overview of herbal medicine and dietary supplements", section on 'Accuracy of labeling'</a>.)</p><p class="headingAnchor" id="H606909468"><span class="h3">Other forms of androgen stimulation</span><span class="headingEndMark"> — </span>Another approach to increasing endogenous testosterone concentrations is by taking exogenous human chorionic gonadotropin (hCG), antiestrogens such as <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> or <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a>, or aromatase inhibitors. These drugs result in an increase in serum testosterone concentrations, and all are banned by the World Anti-Doping Agency (WADA) [<a href="#rid31">31</a>]. (See <a class="local">'Estrogen blockade'</a> below.)</p><p class="headingAnchor" id="H182909591"><span class="h4">Estrogen blockade</span><span class="headingEndMark"> — </span>Estrogen blockade with drugs that block estrogen action or synthesis is another strategy for raising serum testosterone levels in men. They are most commonly coadministered with androgens to prevent gynecomastia. Drugs in this category include antiestrogens and aromatase inhibitors. (See  <a class="medical medical_review" href="/z/d/html/7467.html" rel="external">"Management of gynecomastia", section on 'Pharmacologic therapy'</a>.)</p><p class="headingAnchor" id="H182909641"><span class="h5">Antiestrogens</span><span class="headingEndMark"> — </span>Antiestrogens bind to and block the estrogen receptor. The original antiestrogens included the nonsteroidal drugs <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> and <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>. These drugs are also referred to as selective estrogen receptor modulators (SERMs); they have estrogen agonist properties in some tissues and estrogen antagonist properties in others. (See  <a class="medical medical_review" href="/z/d/html/762.html" rel="external">"Mechanisms of action of selective estrogen receptor modulators and down-regulators"</a>.)</p><p><a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">Tamoxifen</a> is an antiestrogen that is sometimes used off-label (10 to 20 mg/day) to treat adolescents and adults with painful gynecomastia (see  <a class="medical medical_review" href="/z/d/html/7467.html" rel="external">"Management of gynecomastia", section on 'Selective estrogen receptor modulators (SERMs)'</a>). Similar doses are used by bodybuilders and other athletes taking testosterone in order to prevent gynecomastia that develops because testosterone is converted to estradiol. Some dietary supplements on the market have been found to contain variable doses of tamoxifen (although they are not labeled as such) [<a href="#rid32">32</a>]. In one product, EstoSuppress, the amount of tamoxifen in two tablets, the recommended daily dose, varied from 0 mg to 7.6 mg. A dose of 7.6 mg is close to the therapeutic dose (10 to 20 mg) used clinically for men with gynecomastia and for men with breast cancer; in men with breast cancer, tamoxifen has been associated with sexual dysfunction and an increased risk of venous thromboembolism [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/779.html" rel="external">"Breast cancer in men", section on 'Endocrine therapy'</a>.)</p><p class="headingAnchor" id="H182909711"><span class="h5">Aromatase inhibitors</span><span class="headingEndMark"> — </span>Aromatase inhibitors are steroidal or nonsteroidal agents that block the conversion of androgens to estrogen. Examples include androstenedione analogs, such as testolactone, and the nonsteroidal agents <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a> and <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a>. Although they are not very effective, they are used to reduce the development of gynecomastia and to attempt to elevate the serum testosterone concentration (see  <a class="medical medical_review" href="/z/d/html/7467.html" rel="external">"Management of gynecomastia", section on 'Aromatase inhibitors'</a>). Modest elevations of serum testosterone are seen with aromatase inhibitor use in men, but an effect on muscle strength has not been demonstrated [<a href="#rid34">34</a>]. There are sensitive assays available to detect aromatase inhibitors and antiestrogens [<a href="#rid35">35</a>]. These can be detected in urine by gas chromatography/mass spectrometry [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H606911831"><span class="h4">Use of hCG</span><span class="headingEndMark"> — </span>Exogenous human chorionic gonadotropin (hCG), which binds to the luteinizing hormone (LH) receptor and stimulates the Leydig cells of the testes to secrete testosterone, has also been used by athletes. hCG leads to production of endogenous testosterone in the normal ratio to epitestosterone, making its use more difficult to distinguish from normal secretion [<a href="#rid31">31</a>]. LH has a very short half-life and is not likely to be abused.</p><p>Side effects of hCG include edema and gynecomastia. Detection of hCG is discussed below. (See <a class="local">'Detection of banned substances'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>It seems intuitive that androgens increase muscle mass and muscle strength, given the obvious differences between males and females. Administration of supraphysiologic doses of exogenous testosterone to healthy young men has been shown to increase their muscle strength. However, there is no evidence that the androgen precursor, androstenedione, increases muscle strength, and the evidence for an effect of DHEA is conflicting.</p><p class="bulletIndent1"><span class="glyph">●</span>In one placebo-controlled, double-blind study of exogenous testosterone, 43 normal men were randomly assigned to one of four groups: strength-training exercise with either 600 mg of testosterone enanthate once per week (approximately six times a replacement dose) or placebo, or no exercise with either testosterone or placebo [<a href="#rid37">37</a>]. Testosterone treatment increased fat-free mass and muscle strength, both in men who exercised and in men who did not, but more so in those who exercised simultaneously.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second, double-blind trial of exogenous testosterone, 61 healthy eugonadal men were randomly assigned to one of five groups, each treated with a gonadotropin-releasing hormone (GnRH) agonist to suppress endogenous testosterone secretion and one of five weekly doses of testosterone enanthate from 25 to 600 mg [<a href="#rid38">38</a>]. Testosterone administration was associated with a dose-dependent increase in leg press strength and leg power. Improvements in strength and power correlated with serum total testosterone concentrations. Muscle fatigability did not change with treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, in a randomized, placebo-controlled trial of androstenedione in normal men, administration of 100 mg three times daily for eight weeks did not increase muscle strength; however, serum testosterone concentrations were not increased by this regimen [<a href="#rid22">22</a>]. Similarly, in a placebo-controlled study of 50 healthy men ages 35 to 65 years receiving androstenedione or androstanediol (200 mg/day), neither hormone altered body composition or muscle strength compared with placebo [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Results from placebo-controlled studies of DHEA in normal men have been mixed. In one study in which 40 trained men were given DHEA (100 mg/day), androstenedione, or placebo, there were no differences in fat-free mass and muscle mass between the two drug groups and the placebo group [<a href="#rid25">25</a>]. In another trial, nine men and 10 women were randomized to receive 100 mg of DHEA or placebo daily for six months and then crossed over for another six months [<a href="#rid26">26</a>]. In the men, but not the women, knee and lumbar back strength increased during DHEA treatment compared with placebo.</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Side effects and complications</span><span class="headingEndMark"> — </span>All androgens have some side effects when taken in high doses; other side effects depend upon the structure of the androgen or the steroids to which it is converted  (<a class="graphic graphic_table graphicRef97631" href="/z/d/graphic/97631.html" rel="external">table 1</a>). Some side effects occur only in women.</p><p class="headingAnchor" id="H436157322"><span class="h3">Cardiovascular</span><span class="headingEndMark"> — </span>The effect of high doses of androgens on cardiac function is uncertain.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac hypertrophy</strong> – Several case reports describe sudden death in young athletes who had no previously known heart disease but who were taking androgens; cardiac hypertrophy or myocarditis were found at autopsy [<a href="#rid40">40,41</a>]. It is not possible to establish causality in these sporadic cases (see  <a class="medical medical_review" href="/z/d/html/986.html" rel="external">"Athletes: Overview of sudden cardiac death risk and sport participation"</a>). There are also reports of left ventricular hypertrophy in body builders and power lifters, but most of these studies have not been randomized or controlled for degree of exercise, which itself can affect the degree of cardiac hypertrophy [<a href="#rid42">42</a>]. In one randomized, placebo-controlled trial, eight body builders treated with nandrolone decanoate showed no difference in several echocardiographic parameters at the end of eight weeks from those treated with placebo, but this study was limited by the small numbers of subjects and short duration [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipids</strong> – Although physiologic doses of testosterone have no consistent effects on serum lipid concentrations, pharmacologic doses of androgens, especially 17-alpha-alkylated androgens administered orally, decrease serum high-density lipoprotein (HDL) cholesterol and increase low-density lipoprotein (LDL) cholesterol concentrations  (<a class="graphic graphic_table graphicRef97631" href="/z/d/graphic/97631.html" rel="external">table 1</a>) [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1">In a study of normal men aged 30 to 56 years given androstenedione (300 mg/day for 28 days), serum HDL cholesterol concentrations decreased by 15 percent, a change that, in the general population, would predict an increase in risk of coronary heart disease [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemostatic system</strong> – Androgen administration is also associated with activation of the hemostatic system, as illustrated in a study of 49 weight lifters in whom androgen use was ascertained by history and urine testing. The confirmed steroid users had a higher percentage of abnormally high thrombin-antithrombin complexes in plasma than nonusers (16 versus 6 percent, p = 0.01); higher plasma concentrations of prothrombin fragment 1 (44 versus 24 percent, p&lt;0.001), antithrombin III (22 versus 6 percent, p = 0.005), and protein S (19 versus 0 percent); and lower plasma concentrations of tissue plasminogen activator and its inhibitor [<a href="#rid45">45</a>]. The importance of hemostatic system activation with regard to risk of thrombosis is unclear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythropoiesis</strong> – Testosterone stimulates erythropoiesis, and in men made hypogonadal by administration of a GnRH agonist, it increases hemoglobin and hematocrit in a dose-dependent manner [<a href="#rid46">46</a>]. Erythrocytosis is a well-recognized side effect of treatment of hypogonadism with physiologic doses of testosterone. Erythrocytosis, sometimes to a severe degree, has also been reported in association with administration of pharmacologic doses of androgens but only in case reports [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism"</a>.)</p><p></p><p class="headingAnchor" id="H436157491"><span class="h3">Neuropsychiatric</span><span class="headingEndMark"> — </span>Many psychological abnormalities have been described, both in the medical literature and anecdotally, in men taking high doses of androgens  (<a class="graphic graphic_table graphicRef97631" href="/z/d/graphic/97631.html" rel="external">table 1</a>). Most descriptions are uncontrolled, although in one study an attempt was made to compare men taking and not taking androgens [<a href="#rid48">48</a>]. One hundred sixty men recruited from gyms responded to a questionnaire about androgen use and psychiatric symptoms. Psychiatric symptoms, including major mood disorders and aggressive behavior, were more common in the men who had taken androgens than in those who had never taken androgens, and among the former, the symptoms were more common when they were taking androgens. Controlled studies using supraphysiologic doses of testosterone enanthate, although lower than those athletes often use, for up to six months, demonstrate no [<a href="#rid37">37,49,50</a>] or minimal [<a href="#rid51">51</a>] psychological abnormalities.</p><p>Several studies describe an association between nonmedical use of androgens and risky or even criminal behavior. In mail surveys of approximately 10,000 to 15,000 college students from 1993 to 2001, nonmedical use of androgens was associated with cigarette smoking, other illicit drug use, drinking and driving, and Diagnostic and Statistical Manual of Mental Disorders, 4<sup>th</sup> edition (DSM-IV) alcohol use disorder [<a href="#rid8">8,52</a>].</p><p>Examination of data from the Longitudinal Study of Adolescent Health, in which 6823 adolescents were surveyed on three occasions between 7<sup>th</sup> and 12<sup>th</sup> grade, demonstrated that nonmedical use of androgens was associated with violent behavior such as physical fighting [<a href="#rid53">53</a>].</p><p>Women who use anabolic steroids have described both hypomanic and depressive symptoms [<a href="#rid54">54,55</a>]. In addition, some women report rigid dietary practices (referred to as "eating disorder, bodybuilder type"), nontraditional gender roles, and dissatisfaction/preoccupation with their bodies (referred to as "muscle dysphoria").</p><p class="headingAnchor" id="H436157650"><span class="h3">Reproductive (women)</span><span class="headingEndMark"> — </span>In women, side effects of androgens include acne, hirsutism, temporal hair recession in a male pattern, clitoromegaly, and deepening of the voice  (<a class="graphic graphic_table graphicRef97631" href="/z/d/graphic/97631.html" rel="external">table 1</a>). Voice changes are irreversible [<a href="#rid7">7</a>]. Although not well studied, many women also develop oligomenorrhea or amenorrhea. Breast atrophy may also be seen.</p><p class="headingAnchor" id="H606911486"><span class="h3">Reproductive (men)</span></p><p class="headingAnchor" id="H436158875"><span class="h4">Hypogonadism following discontinuation of exogenous androgens</span><span class="headingEndMark"> — </span>In men, all androgens suppress gonadotropin secretion and endogenous testicular function, both testosterone and sperm production  (<a class="graphic graphic_table graphicRef97631" href="/z/d/graphic/97631.html" rel="external">table 1</a>). Testicular volume eventually decreases with chronic use of androgens, and spermatogenesis and fertility become greatly diminished.</p><p>Chronic exogenous androgen use can cause prolonged suppression of gonadotropins and, therefore, result in hypogonadism after the exogenous androgens have been discontinued [<a href="#rid15">15</a>].The prevalence of hypogonadism among exogenous androgen users is not known. However, one retrospective series found that 21 percent of 382 men with hypogonadism presenting for testosterone therapy had previously taken these drugs [<a href="#rid56">56</a>]. This observation highlights the importance of obtaining a careful drug history before prescribing testosterone to men with apparent hypogonadism. (See  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Appropriate candidates'</a>.)</p><p>Among men who stop using androgens, the sperm count usually returns to normal within four months after discontinuation [<a href="#rid57">57</a>] but may take more than a year [<a href="#rid58">58</a>]. Gonadotropin and testosterone secretion remain suppressed for a few months after androgens are discontinued. Younger men may recover more quickly than older men [<a href="#rid15">15</a>]. Some men request hCG during recovery, but it should not be prescribed, because it has not been shown to speed this process and because some men say they want to stop taking androgens as an excuse to get a prescription for hCG.</p><p class="headingAnchor" id="H436157316"><span class="h4">Gynecomastia</span><span class="headingEndMark"> — </span>Gynecomastia occurs because testosterone is converted to estradiol via the action of the aromatase enzyme complex, so that high doses of testosterone result in high serum estradiol concentrations. Androgens that have been 5-alpha reduced, such as dihydrotestosterone, and synthetic androgens in which the A ring has been modified cannot be aromatized and therefore cannot be converted to estrogens and do not cause gynecomastia.</p><p>As noted above, many male androgen abusers also take antiestrogens or aromatase inhibitors to prevent gynecomastia. (See <a class="local">'Estrogen blockade'</a> above.)</p><p class="headingAnchor" id="H436157656"><span class="h3">Other</span><span class="headingEndMark"> — </span>Androgen abuse has been associated with a number of other adverse effects as well, including  (<a class="graphic graphic_table graphicRef97631" href="/z/d/graphic/97631.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Sporadic case reports describe infections due to injection of androgens, including local abscess at the site of injection, septic arthritis, hepatitis B and C, and human immunodeficiency virus (HIV) infection from sharing of needles [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostate</strong> – Because the prostate is a testosterone-dependent gland, there is concern that the high doses of androgens that athletes take might increase the risk of benign prostatic hypertrophy and prostate cancer. A meta-analysis of replacement doses of testosterone in hypogonadal men did not show such increased risks [<a href="#rid60">60</a>], but the risk in athletes who take large doses of androgens has not been reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tendon rupture</strong> – The risk of tendon rupture (eg, triceps or biceps tendon rupture) appears to be increased in weight lifters who use androgens [<a href="#rid61">61-63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epiphyseal closure</strong> – Pharmacologic doses of testosterone or other androgens that can be aromatized to estrogens hasten epiphyseal closure in adolescents whose epiphyses have not yet closed. The frequency of androgen use in adolescents is discussed above. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatic side effects</strong> – Hepatic side effects occur only with oral 17-alpha-alkylated androgens and include high serum concentrations of liver enzymes, cholestatic jaundice, and peliosis hepatis, characterized by blood-filled hepatic cysts. Hepatomas have also been reported, but the number of cases is few and causality is uncertain.</p><p></p><p class="headingAnchor" id="H21"><span class="h2">Detection of banned substances</span><span class="headingEndMark"> — </span>Exogenous administration of pharmacologic doses of androgens might be suspected in a man who competes in a sport in which excess androgens are perceived as improving performance and who has small testes, low sperm count, high hematocrit and hemoglobin values, undetectable serum LH, and low serum sex hormone-binding globulin (SHBG) concentration. In a woman, androgen abuse might be suspected in an athlete with hirsutism, balding, or acne. In both males and females, androgen abuse might be suspected in those who appear excessively muscular. Androgen use can be detected in the urine of such patients by one of several tests, depending upon the compound to be tested. Details of urine collection for testing are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15454.html" rel="external">"Prohibited non-hormonal performance-enhancing drugs in sport", section on 'Urine testing'</a>.)</p><p>When a sports organization identifies a positive screening test in an athlete, it will take further action according to its own regulations (or anti-doping code) and the laws of the country where the testing occurred. These organizations may also issue fines and bans from participation in future events.</p><p>The WADA utilizes two main methods for detecting testosterone [<a href="#rid35">35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Testosterone/epitestosterone ratio – Testosterone taken exogenously cannot be distinguished from that produced endogenously by the usual methods for measuring testosterone, radioimmunoassay and tandem mass spectroscopy, so other methods must be used. The conventional method is to determine the urinary ratio of testosterone glucuronide to its endogenous epimer, epitestosterone glucuronide (T/E ratio). Normally the ratio is 1:1 to 3:1, but subjects taking exogenous testosterone, which suppresses the production of both testosterone and epitestosterone and replaces it only with testosterone, have higher ratios, usually &gt;6:1 [<a href="#rid64">64</a>]. However, a T/E ratio of &gt;4:1 is considered evidence of doping by WADA.</p><p></p><p class="bulletIndent1">The limitation of the T/E ratio is shown by the much greater between, than within, subject variability [<a href="#rid65">65</a>]. The reason for this difference has been shown to result from heterozygosity in the uridine diphosphoglucuronosyl transferase UGT2B17 that converts testosterone to testosterone glucuronide  (<a class="graphic graphic_figure graphicRef50268" href="/z/d/graphic/50268.html" rel="external">figure 2</a>) [<a href="#rid66">66</a>]. No such heterozygosity apparently exists in the UGT2B17 that converts epitestosterone to epitestosterone glucuronide. The consequence is that a man who has a deletion of both copies of this enzyme converts testosterone to testosterone glucuronide poorly, so after an injection of exogenous testosterone, his T/E ratio is much lower than a man who has two copies of the gene. In one study, this deletion was more common in Korean than Swedish males [<a href="#rid67">67</a>]. Conventional monitoring by this ratio, therefore, is much less likely to detect the athlete who has both copies deleted and who takes exogenous testosterone than the athlete who has two normal copies of the gene  (<a class="graphic graphic_figure graphicRef50268" href="/z/d/graphic/50268.html" rel="external">figure 2</a>). The investigators who elucidated this heterozygosity proposed setting normal ranges for the T/E ratio depending on whether or not the athlete has two, one, or no copies of this gene. In addition, some single nucleotide polymorphisms in the promoter region of the <em>CYP17</em> gene are associated with higher T/E ratio, which may explain why some normal individuals have naturally high T/E ratios in the absence of androgen abuse [<a href="#rid68">68</a>]. Another limitation of the T/E ratio is that athletes can mask testosterone use by taking gonadotropins or epitestosterone, which can reduce the T/E ratio [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Carbon 13/carbon 12 ratio – The method currently considered most accurate is determination of the ratio of carbon 13 (13C) to carbon 12 (12C) in urinary metabolites of testosterone using isotope ratio mass spectrometry. This method is used to confirm exogenous testosterone use in men with a T/E ratio &gt;4. The rationale is that pharmacologic testosterone preparations are synthesized from plant sterols, which have a lower ratio of 13C to 12C than do endogenous testosterones [<a href="#rid70">70</a>]. This method will show a low 13C to 12C ratio even if an athlete takes epitestosterone in an attempt to mask taking testosterone.</p><p></p><p>Thus, suspicion for exogenous testosterone use should be high in an athlete with a normal or elevated T/E ratio and low 13C to 12C ratio. These tests are offered by official testing bodies but not clinically. Offering them outside of the official process would alert those taking androgens.</p><p>Androgens other than testosterone can be detected by gas chromatography and mass spectrometry if the athlete is still taking the compound(s) at the time of testing [<a href="#rid35">35</a>]. These tests are usually performed at commercial laboratories. Androgens other than testosterone also cause a high T/E ratio since androgens suppress endogenous testosterone production.</p><p>SARMs can be detected in urine. This detection can be accomplished through solid-phase extraction followed by liquid chromatography-tandem mass spectrometry utilizing electrospray ionization [<a href="#rid71">71</a>].</p><p>hCG can be detected by immunoextraction of urine and mass spectrometry. The proposed male cutoff is 5 international units/L. Because hCG is elevated in patients with testicular cancer, it may be a false positive for doping in this condition [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H606912472"><span class="h3">Avoiding detection</span><span class="headingEndMark"> — </span>Athletes are continually finding ways to avoid detection [<a href="#rid71">71</a>]. The most common way is to discontinue the drug before testing will occur. Screening tests can also be manipulated by urine substitutes, urine dilution, refusing to provide samples of urine or blood, and placing substances in the urethra to mask the samples. As an example, athletes may concomitantly take diuretics and increase fluid intake to dilute urine.</p><p>Other indicators of sample tampering include urine at room temperature from a newly obtained sample or specific gravity out of the range of normal. If the screening tests detect abnormal results, typically more advanced techniques such as liquid chromatography and mass spectrometry are used to confirm the results [<a href="#rid2">2,72</a>].</p><p>In one highly publicized case, a private laboratory synthesized an androgenic steroid specifically designed to avoid detection. The drug was identified when a syringe filled with it was provided to the US Anti-Doping Agency (USADA), which eventually determined that the drug was tetrahydrogestrinone [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H606909303"><span class="h3">Therapeutic use exemption</span><span class="headingEndMark"> — </span>The WADA and USADA allow athletes to compete if they are taking a banned medication, provided the medication is required for therapeutic purposes. In this situation, they grant a therapeutic use exemption after reviewing a form completed by the athlete's clinician [<a href="#rid74">74</a>]. The clinician must state that the athlete would experience a significant health problem if not allowed to take the prohibited medication, the medication would not produce significant enhancement of performance, and there is no reasonable therapeutic alternative. An example is an athlete who takes testosterone because he has had bilateral orchiectomy for testicular cancer.</p><p class="headingAnchor" id="H436157792"><span class="h1">APPROACH TO THE PATIENT TAKING EXOGENOUS ANDROGENS</span></p><p class="headingAnchor" id="H436159210"><span class="h2">Challenges</span><span class="headingEndMark"> — </span>The challenge in identifying athletes using drugs, in particular androgens, to attempt to enhance performance is that individuals are unlikely to tell their clinicians that they are using hormonal performance enhancement. The overall therapeutic alliance is key to obtaining the necessary medical history. Clinicians should educate athletes about the potential harms of using these drugs.</p><p>Few users of these drugs seek treatment [<a href="#rid7">7</a>]. However, for those who do, stopping them is challenging. Many individuals struggle with body image disorders (muscle dysmorphia) as well as depression related to their hypogonadism, and they need psychologic intervention<strong> </strong>[<a href="#rid75">75</a>]. Recovery of the hypothalamic-pituitary-testicular axis may be prolonged.</p><p>The American Academy of Family Physicians (AAFP), American Medical Association (AMA) Guidelines for Adolescent Preventive Services (GAPS), and American Academy of Pediatrics (AAP) all suggest that clinicians discuss the dangers of drug abuse with children and adolescents and include questions about substance abuse as a part of routine adolescent visits. Clinicians may also suspect abuse of androgens in adolescents who have problem behavior (eg, fighting, other substance abuse, risky sexual behaviors) [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H436159216"><span class="h2">When to suspect exogenous androgen use</span><span class="headingEndMark"> — </span>Exogenous administration of pharmacologic doses of androgens might be suspected in an athlete who:</p><p class="bulletIndent1"><span class="glyph">●</span>Competes in a sport or activity in which excess androgens are perceived as improving performance. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exhibits a change in behavior, such as depression, irritability or aggression. (See <a class="local">'Neuropsychiatric'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Develops high hematocrit, undetectably low serum luteinizing hormone (LH) concentration, and low sex hormone-binding globulin (SHBG). (See <a class="local">'Cardiovascular'</a> above.)</p><p></p><p>Individuals who should be suspected of use include:</p><p class="bulletIndent1"><span class="glyph">●</span>Men who exhibit a more rapid increase in muscle strength and mass compared with athletes who do not use androgens, gynecomastia, acne, small testes, and low sperm density. Tendon rupture is sometimes seen. (See <a class="local">'Reproductive (men)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women who develop irregular menstrual cycles, hirsutism, acne, breast atrophy, temporal hair recession, deepening of the voice, clitoromegaly, increased muscle mass, and decrease in body fat. (See <a class="local">'Reproductive (women)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children or adolescents who experience signs of early puberty (development of secondary sexual characteristics) followed by premature closure of epiphyses and a decrease in final height. (See <a class="local">'Other'</a> above.)</p><p></p><p>Androgen use can be detected in such patients by one of several tests, depending upon the compound to be tested. (See <a class="local">'Detection of banned substances'</a> above.)</p><p class="headingAnchor" id="H436157859"><span class="h2">Stopping</span><span class="headingEndMark"> — </span>Men who take hormones, especially androgens, to enhance athletic performance are usually reluctant to stop, even when they no longer are engaged in the activity for which they took the drugs originally. However, if a man does not ask for advice about stopping, a clinician should encourage him to do so but advise him that he will likely become hypogonadal for a period, perhaps many months, before his pituitary-testicular axis recovers. Symptoms of androgen deficiency are likely to occur after stopping (depression, fatigue, decreased libido, sexual dysfunction).</p><p class="headingAnchor" id="H436159222"><span class="h3">Recovery of testicular function</span><span class="headingEndMark"> — </span>These men often ask clinicians for human chorionic gonadotropin (hCG) or <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> to hasten this process, but there is no evidence that either does so. The clinician should also offer to follow the recovery by measuring the serum testosterone concentration, initially three months after discontinuation of the drug and, if the value is not normal, then periodically thereafter.</p><p>If fertility is desired, sperm density should be tested as well, also beginning at three months. Clinicians should be warned, however, that some men say they want to stop taking androgens as an excuse to get a prescription for hCG. When the clinician does not prescribe hCG, they may not return.</p><p class="headingAnchor" id="H2004005645"><span class="h2">Reporting illicit androgen use</span><span class="headingEndMark"> — </span>If a patient admits to using a drug to enhance athletic performance or if these substances are detected by testing, the clinician should attempt to educate the patient on the risks of continued use, although most patients who take these drugs think that they know more about them than the clinicians. If the drug is illicit, the clinician is not legally obligated to report, even if the patient is a minor. (See  <a class="medical medical_review" href="/z/d/html/106.html" rel="external">"Confidentiality in adolescent health care"</a>.)</p><p class="headingAnchor" id="H1490058376"><span class="h2">Clinician's culpability</span><span class="headingEndMark"> — </span>A clinician can be found guilty of anti-doping violations for prescribing banned substances to enhance athletic performance, but not if a therapeutic use exemption has been filed. Sports organizations may not be sympathetic and can administer harsh suspensions or penalties to an athlete for doping infringements, even if taking a banned substance for an urgent condition [<a href="#rid77">77</a>]. Due to difficulties in proving intent to cheat, the World Anti-Doping Agency (WADA) enforces strict liability for positive test results. Clinicians may be asked by an athlete to complete exemption forms prior to sports competitions in order to enable athletes to take WADA-banned substances that are required for medical treatment. In urgent cases, either a retroactive or a retrospective exemption form may be applied for and approved by the appropriate sport committee.</p><p class="headingAnchor" id="H364314517"><span class="h1">OTHER HORMONES</span></p><p class="headingAnchor" id="H23"><span class="h2">Growth hormone</span><span class="headingEndMark"> — </span>Growth hormone, like androgens, has been linked to many prominent athletes in sports, including baseball, swimming, and cycling [<a href="#rid12">12</a>]. In addition, approximately 5 percent of United States high school students use growth hormone [<a href="#rid2">2</a>]. Growth hormone use by high school athletes in Germany is lower (0.4 percent) [<a href="#rid78">78</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical effects</strong> – Athletes take <a class="drug drug_general" data-topicid="9456" href="/z/d/drug information/9456.html" rel="external">recombinant human growth hormone</a> (rhGH) because of its demonstrated effects on body composition (more muscle, less fat) [<a href="#rid79">79</a>]. In earlier studies, growth hormone administration was not shown to be effective for either strength [<a href="#rid80">80,81</a>] or endurance [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1">In the largest study to-date in recreational athletes, men were randomly assigned to receive placebo, growth hormone (2 mg/day subcutaneously), testosterone (250 mg/week intramuscularly), or combined treatments, while women were randomly assigned to receive either placebo or growth hormone (2 mg/day) [<a href="#rid83">83</a>]. In both males and females, growth hormone significantly reduced fat mass, increased lean body mass through an increase in extracellular water, and improved sprint capacity but not strength, power, or endurance. The improvement in sprint capacity was greater when growth hormone was coadministered with testosterone to men. The effects of growth hormone disappeared after six weeks of being discontinued. The clinical significance of the increase in one physical performance parameter, but not others, in spite of supraphysiologic doses of both drugs is uncertain.</p><p></p><p class="bulletIndent1">Growth hormone would be expected to cause acromegaly if given in high doses long enough, but no such cases have been reported. Cancer is another potential concern as epidemiologic data suggest an association between serum concentrations of insulin-like growth factor 1 (IGF-1) and cancer risk. (See  <a class="medical medical_review" href="/z/d/html/6938.html" rel="external">"Risk factors for prostate cancer", section on 'Insulin and insulin-like growth factor'</a>.)</p><p></p><p class="bulletIndent1">A review of studies in which growth hormone was administered to healthy males and females showed an increased incidence of soft tissue edema compared with those not treated [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Growth hormone can cause insulin resistance, hyperglycemia, diabetes, sodium retention, hypertension, cardiomegaly, premature epiphyseal closure, myopathy, carpal tunnel syndrome, and swelling of the hands [<a href="#rid12">12,84,85</a>]. (See  <a class="medical medical_review" href="/z/d/html/6641.html" rel="external">"Growth hormone deficiency in adults", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent1">Weightlifters who abuse growth hormone were found to have a high use of other risky drugs, such as opioids, cocaine, and others [<a href="#rid86">86</a>], similar to men who abuse androgens.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Detection methods</strong> – Detection of growth hormone can occur only through the blood because less than 0.1 percent is excreted through urine. Two methods are used to detect use of growth hormone by athletes [<a href="#rid87">87</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Markers of growth hormone action, such as IGF-1 and procollagen type III N-terminal propeptide (P-III-NP) – One study showed that when growth hormone in doses of 0.033 or 0.066 mcg/kg was administered daily for four weeks to healthy males and females, their serum concentrations of IGF-1 and P-III-NP were readily distinguishable from subjects administered placebo [<a href="#rid88">88</a>]. These effects were shown in a subsequent study to be greater in men than in women and were amplified by concomitant testosterone administration [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Growth hormone isoforms – The pituitary gland normally secretes a variety of growth hormone isoforms, including a 20 kDa form and a 22 kDa form in monomers and dimers. However, rhGH consists only of the 22 kDa monomer. Immunoassays have been developed that can recognize either the 22 kDa form selectively or all of the isoforms nonselectively. Since administration of rhGH suppresses endogenous growth hormone secretion, an elevated ratio of the selective 22 kDa assay to growth hormone measured by the nonselective assay indicates administration of exogenous rhGH [<a href="#rid87">87</a>]. The first athlete detected using this test, a British rugby player, was reported in 2010 [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The athlete biological passport (ABP), an approach that complements traditional drug testing, is based upon monitoring selected biological variables over time to detect the effects of doping rather than the doping substance itself. WADA has introduced ABP guidelines for detection of blood doping and androgen use; ABPs for growth hormone detection are in development. One study reported the feasibility of developing profiles of human growth hormone biomarkers (IGF-1, P-III-NP, and growth hormone isoforms), ie, an ABP for identifying human growth hormone abuse in individual athletes [<a href="#rid91">91</a>]. Recreational athletes (n = 35) were randomized to one of three different doses of recombinant growth hormone or placebo for three weeks, with 14 tests over three months. The ABP approach identified almost all subjects who had received recombinant growth hormone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth factors (IGF-1 and insulin)</strong> – The rates of IGF-1 and insulin use for performance enhancement are lower than growth hormone [<a href="#rid12">12,92</a>]. IGF-1 should have similar effects to growth hormone, but this has not been studied [<a href="#rid12">12</a>]. Athletes have also begun to use insulin, in particular, short-acting insulins, because of their anabolic effects on muscle.</p><p></p><p class="bulletIndent1">Insulin and IGF-1 may lead to hypoglycemia. In one survey of 20 men who were recruited from gyms and admitted to using androgens, five reported that they also used insulin [<a href="#rid93">93</a>]. They reported ingesting large amounts of sugar after insulin injection to avoid hypoglycemia. Serum concentrations of IGF-1 may be associated with an increased risk of prostate cancer. (See  <a class="medical medical_review" href="/z/d/html/6938.html" rel="external">"Risk factors for prostate cancer", section on 'Insulin and insulin-like growth factor'</a>.)</p><p></p><p class="bulletIndent1">IGF-1 can only be detected through blood. However, no commercial screen tests are available at this time [<a href="#rid12">12</a>]. Detection of insulins can be done in the urine with use of antibody/antigen reactions and liquid chromatography/mass spectrometry. However, it is often difficult to distinguish among human insulin, insulin analogs, and porcine insulin [<a href="#rid71">71</a>].</p><p></p><p class="headingAnchor" id="H364314742"><span class="h2">Erythropoietin</span><span class="headingEndMark"> — </span>Athletes have used methods to increase the oxygen-carrying capacity of the blood and thereby athletic performance for decades, initially by training at high altitudes, then by transfusions, and more recently by hypoxia and administration of drugs such as erythropoietin that stimulate erythropoiesis [<a href="#rid94">94</a>]. Use of these methods in competitive cycling, such as the Tour de France, has been reported widely in the popular press. All increase oxygen transport.</p><p>The first available agent was recombinant human erythropoietin and later <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">darbepoetin alfa</a>, which has a longer half-life. Erythropoietin increases the blood's maximum capacity to transport and utilize oxygen, thereby augmenting aerobic power and physical exercise tolerance [<a href="#rid84">84,94,95</a>].</p><p>Major adverse effects of increased erythropoiesis include myocardial infarction, stroke, and thromboembolic disease [<a href="#rid94">94</a>]. It may also lead to hypertension, antibody-mediated anemia, and polycythemia. (See  <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/1930.html" rel="external">"Pure red cell aplasia (PRCA) due to anti-erythropoiesis-stimulating agent antibodies"</a>.)</p><p>There are indirect and direct methods for detecting erythropoietin. Indirect methods include measurement of total hemoglobin mass, which can increase approximately 10 percent with erythropoietin use [<a href="#rid94">94,96</a>]. Hematocrit and reticulocyte counts may also increase. Erythropoietin can also be detected directly by immunoaffinity chromatography, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), isoelectric focusing, and mass spectrometry [<a href="#rid71">71</a>]. Some users of erythropoietin add proteases in their urine to degrade it [<a href="#rid94">94</a>], but protease inhibitors added to the urine immediately after collection can prevent degradation [<a href="#rid97">97</a>], and specific patterns of degradation suggest their use. Testing is not as well developed for other agents.</p><p class="headingAnchor" id="H680726094"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids alter glucose metabolism and possess anti-inflammatory and analgesic properties, leading some athletes to use them in sporting events [<a href="#rid98">98</a>]. Glucocorticoids are prohibited only within 12 hours in which an athlete is scheduled to participate in a sporting event and through the duration of the event itself. Their use and efficacy are not well documented for performance enhancement. Glucocorticoids may cause hyperglycemia, fluid retention, and acute mood changes (see  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>). In chronic use they can suppress the hypothalamic-pituitary-adrenal axis and lead to reduced muscle mass and weakness, osteoporosis, diabetes, hypertension, weight gain and abdominal obesity, cataracts, and various psychiatric symptoms (eg, hypomania, depression, psychosis). (See  <a class="medical medical_review" href="/z/d/html/124.html" rel="external">"Pharmacologic use of glucocorticoids"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">OTHER PERFORMANCE-ENHANCING METHODS</span><span class="headingEndMark"> — </span>Some athletes take several other drugs and supplements in addition to androgens, growth hormone, and erythropoiesis-stimulating agents to enhance performance. Examples include stimulants, creatine, and beta blockers. Nonhormonal performance-enhancing agents are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15454.html" rel="external">"Prohibited non-hormonal performance-enhancing drugs in sport"</a>.)</p><p>There are several methods of performance enhancement that do not involve taking drugs. Blood transfusions are among the most common [<a href="#rid99">99</a>]. Others include hypoxia induction and gene doping. All of these methods are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15454.html" rel="external">"Prohibited non-hormonal performance-enhancing drugs in sport"</a>.)</p><p class="headingAnchor" id="H3233180576"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117863.html" rel="external">"Society guideline links: Androgens and other banned substances in athletes"</a>.)</p><p class="headingAnchor" id="H23216787"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/85796.html" rel="external">"Patient education: Growth hormone treatment in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86461.html" rel="external">"Patient education: Hormones to boost sports performance: Risks and side effects (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The use of androgens, growth hormone, and other drugs to improve athletic performance is common, even in adolescents. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Virtually all androgens produced for human or veterinary purposes have been taken by athletes  (<a class="graphic graphic_figure graphicRef53955" href="/z/d/graphic/53955.html" rel="external">figure 1</a>). These include testosterone esters, which are usually taken by injection; the 17-alpha-alkylated androgens, which are usually taken orally; androgen precursors; and possibly selective androgen receptor modulators (SARMs). (See <a class="local">'Androgens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exogenous testosterone administration increases serum testosterone concentrations, fat-free mass, and muscle strength. There is no evidence that androstenedione increases muscle strength. The evidence for dehydroepiandrosterone (DHEA) is equivocal. (See <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adverse effects of androgen use include suppression of endogenous testicular function, gynecomastia, erythrocytosis, hepatotoxicity (with 17-alpha-akylated androgens), psychological disorders, a decrease in serum high-density lipoprotein (HDL) (especially with 17-alpha-akylated androgens), coagulation activation, premature epiphyseal fusion (in adolescents), infections, and virilization (in women). (See <a class="local">'Side effects and complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of androgens for nonmedical purposes is associated with risky behavior, such as smoking and alcohol abuse, as well as violent behavior, but no causal relationship has been demonstrated. (See <a class="local">'Neuropsychiatric'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Detection of androgen use by athletes is difficult. The conventional method used is the urinary ratio of testosterone glucuronide to its endogenous epimer, epitestosterone glucuronide (T/E ratio). Normally, the T/E ratio is 1:1 to 3:1; a T/E ratio of &gt;4:1 is considered evidence of doping by the World Anti-Doping Agency (WADA) that requires confirmation. (See <a class="local">'Detection of banned substances'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The utility of the T/E ratio is limited by its significant between-subject variability, due to genetically determined differences in the ability to convert testosterone to testosterone glucuronide. (See <a class="local">'Detection of banned substances'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A man who wishes to stop abusing androgens should be encouraged to do so but warned that he will become hypogonadal for several months or even a year before he recovers endogenous gonadotropin secretion and testicular function. He should be monitored every few months until recovery occurs. Human chorionic gonadotropin (hCG) should not be prescribed, because it has not been shown to speed this process, and because some men say they want to stop taking androgens as an excuse to get a prescription for hCG. (See <a class="local">'Recovery of testicular function'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human growth hormone is also commonly used to enhance athletic performance. Clinical trial data suggest that while lean body mass may be increased by growth hormone use, strength and exercise capacity is not. (See <a class="local">'Growth hormone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Detection of exogenous growth hormone use by athletes is difficult. There are two approaches currently being used: measurement of markers of growth hormone action (insulin-like growth factor 1 [IGF-1] and procollagen type III N-terminal propeptide [P-III-NP]) and measurement of growth hormone isoforms that can distinguish exogenous growth hormone from <a class="drug drug_general" data-topicid="9456" href="/z/d/drug information/9456.html" rel="external">recombinant human growth hormone</a> (rhGH). (See <a class="local">'Growth hormone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythropoietin increases the blood's maximum capacity to transport and utilize oxygen, thereby augmenting aerobic power and physical exercise tolerance. Major adverse effects of erythropoietin include myocardial infarction, stroke, and thromboembolic disease. (See <a class="local">'Erythropoietin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other banned substances and dietary supplements that are often used by athletes include stimulants, insulin, and beta blockers. Creatine is not currently on the list of banned substances of any governing bodies, but the National Collegiate Athletic Association (NCAA) prohibits its distribution to athletes by its member institutions. (See <a class="local">'Other performance-enhancing methods'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 2006; 38:644.</a></li><li><a class="nounderline abstract_t">Sjöqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet 2008; 371:1872.</a></li><li><a class="nounderline abstract_t">Melnik BC. Androgen abuse in the community. Curr Opin Endocrinol Diabetes Obes 2009; 16:218.</a></li><li><a class="nounderline abstract_t">Sagoe D, Molde H, Andreassen CS, et al. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol 2014; 24:383.</a></li><li><a class="nounderline abstract_t">Casey A, Hughes J, Izard RM, Greeves JP. Supplement use by UK-based British Army soldiers in training. Br J Nutr 2014; 112:1175.</a></li><li class="breakAll">final-2011-hrb-active-duty-survey-report reduced.pdf (Accessed on June 23, 2015).</li><li><a class="nounderline abstract_t">Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev 2014; 35:341.</a></li><li><a class="nounderline abstract_t">Buckman JF, Farris SG, Yusko DA. A national study of substance use behaviors among NCAA male athletes who use banned performance enhancing substances. Drug Alcohol Depend 2013; 131:50.</a></li><li><a class="nounderline abstract_t">Ip EJ, Lu DH, Barnett MJ, et al. Psychological and physical impact of anabolic-androgenic steroid dependence. Pharmacotherapy 2012; 32:910.</a></li><li><a class="nounderline abstract_t">Kann L, Kinchen S, Shanklin SL, et al. Youth risk behavior surveillance--United States, 2013. MMWR Suppl 2014; 63:1.</a></li><li class="breakAll">Monitoring the Future - a continuing study of American youth. http://www.monitoringthefuture.org (Accessed on February 15, 2011).</li><li><a class="nounderline abstract_t">Holt RI, Sönksen PH. Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol 2008; 154:542.</a></li><li><a class="nounderline abstract_t">Buckman JF, Yusko DA, White HR, Pandina RJ. Risk profile of male college athletes who use performance-enhancing substances. J Stud Alcohol Drugs 2009; 70:919.</a></li><li><a class="nounderline abstract_t">Hakansson A, Mickelsson K, Wallin C, Berglund M. Anabolic androgenic steroids in the general population: user characteristics and associations with substance use. Eur Addict Res 2012; 18:83.</a></li><li><a class="nounderline abstract_t">Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril 2014; 101:1271.</a></li><li><a class="nounderline abstract_t">Ip EJ, Barnett MJ, Tenerowicz MJ, Perry PJ. The Anabolic 500 survey: characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training. Pharmacotherapy 2011; 31:757.</a></li><li><a class="nounderline abstract_t">Abbate V, Kicman AT, Evans-Brown M, et al. Anabolic steroids detected in bodybuilding dietary supplements - a significant risk to public health. Drug Test Anal 2015; 7:609.</a></li><li class="breakAll">http://list.wada-ama.org/prohibited-in-competition/prohibited-substances/ (Accessed on October 15, 2014).</li><li><a class="nounderline abstract_t">HERSHBERGER LG, SHIPLEY EG, MEYER RK. Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med 1953; 83:175.</a></li><li class="breakAll">The Federal Register - US Department of Justice, Drug Enforcement Administration. Rules regarding the implementation of the Anabolic Steroid Control Act of 2004. http://www.thefederalregister.com/d.p/2005-12-16-05-23907 (Accessed on April 01, 2011).</li><li><a class="nounderline abstract_t">Leder BZ, Longcope C, Catlin DH, et al. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA 2000; 283:779.</a></li><li><a class="nounderline abstract_t">King DS, Sharp RL, Vukovich MD, et al. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. JAMA 1999; 281:2020.</a></li><li><a class="nounderline abstract_t">Brown GA, Vukovich MD, Martini ER, et al. Endocrine responses to chronic androstenedione intake in 30- to 56-year-old men. J Clin Endocrinol Metab 2000; 85:4074.</a></li><li><a class="nounderline abstract_t">Acacio BD, Stanczyk FZ, Mullin P, et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men. Fertil Steril 2004; 81:595.</a></li><li><a class="nounderline abstract_t">Wallace MB, Lim J, Cutler A, Bucci L. Effects of dehydroepiandrosterone vs androstenedione supplementation in men. Med Sci Sports Exerc 1999; 31:1788.</a></li><li><a class="nounderline abstract_t">Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998; 49:421.</a></li><li><a class="nounderline abstract_t">Kohler M, Thomas A, Geyer H, et al. Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne Doping Control Laboratory 2009. Drug Test Anal 2010; 2:533.</a></li><li><a class="nounderline abstract_t">Gao W, Kim J, Dalton JT. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm Res 2006; 23:1641.</a></li><li><a class="nounderline abstract_t">Starcevic B, Ahrens BD, Butch AW. Detection of the selective androgen receptor modulator S-4 (Andarine) in a doping control sample. Drug Test Anal 2013; 5:377.</a></li><li><a class="nounderline abstract_t">Van Wagoner RM, Eichner A, Bhasin S, et al. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA 2017; 318:2004.</a></li><li><a class="nounderline abstract_t">Handelsman DJ. Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport. J Clin Endocrinol Metab 2006; 91:1646.</a></li><li><a class="nounderline abstract_t">Evans-Brown M, Kimergård A, McVeigh J, et al. Is the breast cancer drug tamoxifen being sold as a bodybuilding dietary supplement? BMJ 2014; 348:g1476.</a></li><li><a class="nounderline abstract_t">Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Ann Oncol 2012; 23:1471.</a></li><li><a class="nounderline abstract_t">Handelsman DJ. Indirect androgen doping by oestrogen blockade in sports. Br J Pharmacol 2008; 154:598.</a></li><li><a class="nounderline abstract_t">Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab 2010; 95:1533.</a></li><li><a class="nounderline abstract_t">Mareck U, Geyer H, Guddat S, et al. Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2006; 20:1954.</a></li><li><a class="nounderline abstract_t">Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335:1.</a></li><li><a class="nounderline abstract_t">Storer TW, Magliano L, Woodhouse L, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 2003; 88:1478.</a></li><li><a class="nounderline abstract_t">Broeder CE, Quindry J, Brittingham K, et al. The Andro Project: physiological and hormonal influences of androstenedione supplementation in men 35 to 65 years old participating in a high-intensity resistance training program. Arch Intern Med 2000; 160:3093.</a></li><li><a class="nounderline abstract_t">Hausmann R, Hammer S, Betz P. Performance enhancing drugs (doping agents) and sudden death--a case report and review of the literature. Int J Legal Med 1998; 111:261.</a></li><li><a class="nounderline abstract_t">Kennedy MC, Lawrence C. Anabolic steroid abuse and cardiac death. Med J Aust 1993; 158:346.</a></li><li><a class="nounderline abstract_t">Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart 2004; 90:473.</a></li><li><a class="nounderline abstract_t">Hartgens F, Cheriex EC, Kuipers H. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. Int J Sports Med 2003; 24:344.</a></li><li><a class="nounderline abstract_t">Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261:1165.</a></li><li><a class="nounderline abstract_t">Ferenchick GS, Hirokawa S, Mammen EF, Schwartz KA. Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system. Am J Hematol 1995; 49:282.</a></li><li><a class="nounderline abstract_t">Coviello AD, Kaplan B, Lakshman KM, et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 2008; 93:914.</a></li><li><a class="nounderline abstract_t">Stergiopoulos K, Brennan JJ, Mathews R, et al. Anabolic steroids, acute myocardial infarction and polycythemia: a case report and review of the literature. Vasc Health Risk Manag 2008; 4:1475.</a></li><li><a class="nounderline abstract_t">Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry 1994; 51:375.</a></li><li><a class="nounderline abstract_t">O'Connor DB, Archer J, Hair WM, Wu FC. Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. Physiol Behav 2002; 75:557.</a></li><li><a class="nounderline abstract_t">Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281:E1172.</a></li><li><a class="nounderline abstract_t">Pope HG Jr, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry 2000; 57:133.</a></li><li><a class="nounderline abstract_t">McCabe SE, Brower KJ, West BT, et al. Trends in non-medical use of anabolic steroids by U.S. college students: results from four national surveys. Drug Alcohol Depend 2007; 90:243.</a></li><li><a class="nounderline abstract_t">Beaver KM, Vaughn MG, Delisi M, Wright JP. Anabolic-androgenic steroid use and involvement in violent behavior in a nationally representative sample of young adult males in the United States. Am J Public Health 2008; 98:2185.</a></li><li><a class="nounderline abstract_t">Gruber AJ, Pope HG Jr. Psychiatric and medical effects of anabolic-androgenic steroid use in women. Psychother Psychosom 2000; 69:19.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 484: Performance enhancing anabolic steroid abuse in women. Obstet Gynecol 2011; 117:1016. Reaffirmed 2021.</a></li><li><a class="nounderline abstract_t">Coward RM, Rajanahally S, Kovac JR, et al. Anabolic steroid induced hypogonadism in young men. J Urol 2013; 190:2200.</a></li><li><a class="nounderline abstract_t">Knuth UA, Maniera H, Nieschlag E. Anabolic steroids and semen parameters in bodybuilders. Fertil Steril 1989; 52:1041.</a></li><li><a class="nounderline abstract_t">Gazvani MR, Buckett W, Luckas MJ, et al. Conservative management of azoospermia following steroid abuse. Hum Reprod 1997; 12:1706.</a></li><li><a class="nounderline abstract_t">Aitken C, Delalande C, Stanton K. Pumping iron, risking infection? Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia. Drug Alcohol Depend 2002; 65:303.</a></li><li><a class="nounderline abstract_t">Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95:2560.</a></li><li><a class="nounderline abstract_t">Sollender JL, Rayan GM, Barden GA. Triceps tendon rupture in weight lifters. J Shoulder Elbow Surg 1998; 7:151.</a></li><li><a class="nounderline abstract_t">Cope MR, Ali A, Bayliss NC. Biceps rupture in body builders: three case reports of rupture of the long head of the biceps at the tendon-labrum junction. J Shoulder Elbow Surg 2004; 13:580.</a></li><li><a class="nounderline abstract_t">Kanayama G, DeLuca J, Meehan WP 3rd, et al. Ruptured Tendons in Anabolic-Androgenic Steroid Users: A Cross-Sectional Cohort Study. Am J Sports Med 2015; 43:2638.</a></li><li><a class="nounderline abstract_t">Catlin DH, Cowan DA. Detecting testosterone administration. Clin Chem 1992; 38:1685.</a></li><li><a class="nounderline abstract_t">Sottas PE, Saudan C, Schweizer C, et al. From population- to subject-based limits of T/E ratio to detect testosterone abuse in elite sports. Forensic Sci Int 2008; 174:166.</a></li><li><a class="nounderline abstract_t">Schulze JJ, Lundmark J, Garle M, et al. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab 2008; 93:2500.</a></li><li><a class="nounderline abstract_t">Jakobsson J, Ekström L, Inotsume N, et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 2006; 91:687.</a></li><li><a class="nounderline abstract_t">Schulze JJ, Lorentzon M, Ohlsson C, et al. Genetic aspects of epitestosterone formation and androgen disposition: influence of polymorphisms in CYP17 and UGT2B enzymes. Pharmacogenet Genomics 2008; 18:477.</a></li><li><a class="nounderline abstract_t">Stenman UH, Hotakainen K, Alfthan H. Gonadotropins in doping: pharmacological basis and detection of illicit use. Br J Pharmacol 2008; 154:569.</a></li><li><a class="nounderline abstract_t">Aguilera R, Chapman TE, Starcevic B, et al. Performance characteristics of a carbon isotope ratio method for detecting doping with testosterone based on urine diols: controls and athletes with elevated testosterone/epitestosterone ratios. Clin Chem 2001; 47:292.</a></li><li><a class="nounderline abstract_t">Thevis M, Kohler M, Schänzer W. New drugs and methods of doping and manipulation. Drug Discov Today 2008; 13:59.</a></li><li><a class="nounderline abstract_t">Thomas A, Kohler M, Schänzer W, et al. Determination of Synacthen in urine for sports drug testing by means of nano-ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2009; 23:2669.</a></li><li><a class="nounderline abstract_t">Malvey TC, Armsey TD 2nd. Tetrahydrogestrinone: the discovery of a designer steroid. Curr Sports Med Rep 2005; 4:227.</a></li><li class="breakAll">United States Anti-Doping Agency - Therapeutic Use Exemptions (TUE). http://www.usada.org/tue/ (Accessed on January 11, 2011).</li><li><a class="nounderline abstract_t">Kanayama G, Brower KJ, Wood RI, et al. Treatment of anabolic-androgenic steroid dependence: Emerging evidence and its implications. Drug Alcohol Depend 2010; 109:6.</a></li><li><a class="nounderline abstract_t">Miller KE, Hoffman JH, Barnes GM, et al. Adolescent anabolic steroid use, gender, physical activity, and other problem behaviors*. Subst Use Misuse 2005; 40:1637.</a></li><li><a class="nounderline abstract_t">Orchard JW, Fricker PA, White SL, et al. 4. The use and misuse of performance-enhancing substances in sport. Med J Aust 2006; 184:132.</a></li><li><a class="nounderline abstract_t">Wanjek B, Rosendahl J, Strauss B, Gabriel HH. Doping, drugs and drug abuse among adolescents in the State of Thuringia (Germany): prevalence, knowledge and attitudes. Int J Sports Med 2007; 28:346.</a></li><li><a class="nounderline abstract_t">Liu H, Bravata DM, Olkin I, et al. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med 2008; 148:747.</a></li><li><a class="nounderline abstract_t">Deyssig R, Frisch H, Blum WF, Waldhör T. Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes. Acta Endocrinol (Copenh) 1993; 128:313.</a></li><li><a class="nounderline abstract_t">Yarasheski KE, Campbell JA, Smith K, et al. Effect of growth hormone and resistance exercise on muscle growth in young men. Am J Physiol 1992; 262:E261.</a></li><li><a class="nounderline abstract_t">Berggren A, Ehrnborg C, Rosén T, et al. Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes. J Clin Endocrinol Metab 2005; 90:3268.</a></li><li><a class="nounderline abstract_t">Meinhardt U, Nelson AE, Hansen JL, et al. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Ann Intern Med 2010; 152:568.</a></li><li><a class="nounderline abstract_t">Fernandez MM, Hosey RG. Performance-enhancing drugs snare nonathletes, too. J Fam Pract 2009; 58:16.</a></li><li><a class="nounderline abstract_t">Segura J, Gutiérrez-Gallego R, Ventura R, et al. Growth hormone in sport: beyond Beijing 2008. Ther Drug Monit 2009; 31:3.</a></li><li><a class="nounderline abstract_t">Brennan BP, Kanayama G, Hudson JI, Pope HG Jr. Human growth hormone abuse in male weightlifters. Am J Addict 2011; 20:9.</a></li><li><a class="nounderline abstract_t">Bidlingmaier M, Strasburger CJ. Technology insight: detecting growth hormone abuse in athletes. Nat Clin Pract Endocrinol Metab 2007; 3:769.</a></li><li><a class="nounderline abstract_t">Powrie JK, Bassett EE, Rosen T, et al. Detection of growth hormone abuse in sport. Growth Horm IGF Res 2007; 17:220.</a></li><li><a class="nounderline abstract_t">Nelson AE, Meinhardt U, Hansen JL, et al. Pharmacodynamics of growth hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes. J Clin Endocrinol Metab 2008; 93:2213.</a></li><li><a class="nounderline abstract_t">Travis J. Pharmacology. Growth hormone test finally nabs first doper. Science 2010; 327:1185.</a></li><li><a class="nounderline abstract_t">Equey T, Pastor A, de la Torre Fornell R, et al. Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping. J Clin Endocrinol Metab 2022; 107:649.</a></li><li><a class="nounderline abstract_t">Guha N, Cowan DA, Sönksen PH, Holt RI. Insulin-like growth factor-I (IGF-I) misuse in athletes and potential methods for detection. Anal Bioanal Chem 2013; 405:9669.</a></li><li><a class="nounderline abstract_t">Rich JD, Dickinson BP, Merriman NA, Thule PM. Insulin use by bodybuilders. JAMA 1998; 279:1613.</a></li><li><a class="nounderline abstract_t">Elliott S. Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. Br J Pharmacol 2008; 154:529.</a></li><li><a class="nounderline abstract_t">Spedding M, Spedding C. Drugs in sport: a scientist-athlete's perspective: from ambition to neurochemistry. Br J Pharmacol 2008; 154:496.</a></li><li><a class="nounderline abstract_t">Prommer N, Sottas PE, Schoch C, et al. Total hemoglobin mass--a new parameter to detect blood doping? Med Sci Sports Exerc 2008; 40:2112.</a></li><li><a class="nounderline abstract_t">Lamon S, Robinson N, Sottas PE, et al. Possible origins of undetectable EPO in urine samples. Clin Chim Acta 2007; 385:61.</a></li><li><a class="nounderline abstract_t">Botrè F, Pavan A. Enhancement drugs and the athlete. Neurol Clin 2008; 26:149.</a></li><li><a class="nounderline abstract_t">Pottgiesser T, Echteler T, Sottas PE, et al. Hemoglobin mass and biological passport for the detection of autologous blood doping. Med Sci Sports Exerc 2012; 44:835.</a></li></ol></div><div id="topicVersionRevision">Topic 7475 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16679978" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Anabolic androgenic steroids: a survey of 500 users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18514731" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Use of doping agents, particularly anabolic steroids, in sports and society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19373082" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Androgen abuse in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24582699" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25119518" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Supplement use by UK-based British Army soldiers in training.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25119518" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Supplement use by UK-based British Army soldiers in training.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24423981" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23688842" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A national study of substance use behaviors among NCAA male athletes who use banned performance enhancing substances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23033230" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Psychological and physical impact of anabolic-androgenic steroid dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24918634" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Youth risk behavior surveillance--United States, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24918634" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Youth risk behavior surveillance--United States, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18376417" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Growth hormone, IGF-I and insulin and their abuse in sport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19895768" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk profile of male college athletes who use performance-enhancing substances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22286840" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Anabolic androgenic steroids in the general population: user characteristics and associations with substance use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24636400" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Anabolic steroid-induced hypogonadism: diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21923602" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Anabolic 500 survey: characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25284752" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Anabolic steroids detected in bodybuilding dietary supplements - a significant risk to public health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25284752" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Anabolic steroids detected in bodybuilding dietary supplements - a significant risk to public health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13064212" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13064212" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10683057" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Oral androstenedione administration and serum testosterone concentrations in young men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10359391" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095435" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Endocrine responses to chronic androstenedione intake in 30- to 56-year-old men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15037408" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10613429" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effects of dehydroepiandrosterone vs androstenedione supplementation in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9876338" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21204286" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne Doping Control Laboratory 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16841196" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23427117" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Detection of the selective androgen receptor modulator S-4 (Andarine) in a doping control sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29183075" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16478815" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24524927" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Is the breast cancer drug tamoxifen being sold as a bodybuilding dietary supplement?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22085764" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18500381" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Indirect androgen doping by oestrogen blockade in sports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20139230" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Androgen abuse in athletes: detection and consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16715475" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8637535" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12679426" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11074738" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The Andro Project: physiological and hormonal influences of androstenedione supplementation in men 35 to 65 years old participating in a high-intensity resistance training program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9728754" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Performance enhancing drugs (doping agents) and sudden death--a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8474379" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Anabolic steroid abuse and cardiac death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15084526" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cardiac effects of anabolic steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12868045" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2915439" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Contrasting effects of testosterone and stanozolol on serum lipoprotein levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7639272" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18160461" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of graded doses of testosterone on erythropoiesis in healthy young and older men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19337562" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Anabolic steroids, acute myocardial infarction and polycythemia: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8179461" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12062320" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701431" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Testosterone dose-response relationships in healthy young men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10665615" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17512138" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Trends in non-medical use of anabolic steroids by U.S. college students: results from four national surveys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18923108" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Anabolic-androgenic steroid use and involvement in violent behavior in a nationally representative sample of young adult males in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10601831" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Psychiatric and medical effects of anabolic-androgenic steroid use in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422881" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : ACOG Committee Opinion No. 484: Performance enhancing anabolic steroid abuse in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23764075" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Anabolic steroid induced hypogonadism in young men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2512180" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Anabolic steroids and semen parameters in bodybuilders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9308797" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Conservative management of azoospermia following steroid abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11841901" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pumping iron, risking infection? Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20525906" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9593095" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Triceps tendon rupture in weight lifters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15383821" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Biceps rupture in body builders: three case reports of rupture of the long head of the biceps at the tendon-labrum junction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26362436" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ruptured Tendons in Anabolic-Androgenic Steroid Users: A Cross-Sectional Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1525998" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Detecting testosterone administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485185" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : From population- to subject-based limits of T/E ratio to detect testosterone abuse in elite sports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18334593" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16332934" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18496127" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Genetic aspects of epitestosterone formation and androgen disposition: influence of polymorphisms in CYP17 and UGT2B enzymes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18414398" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Gonadotropins in doping: pharmacological basis and detection of illicit use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11159778" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Performance characteristics of a carbon isotope ratio method for detecting doping with testosterone based on urine diols: controls and athletes with elevated testosterone/epitestosterone ratios.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18190865" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : New drugs and methods of doping and manipulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19630025" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Determination of Synacthen in urine for sports drug testing by means of nano-ultra-performance liquid chromatography/tandem mass spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16004834" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Tetrahydrogestrinone: the discovery of a designer steroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16004834" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Tetrahydrogestrinone: the discovery of a designer steroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20188494" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Treatment of anabolic-androgenic steroid dependence: Emerging evidence and its implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16253932" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Adolescent anabolic steroid use, gender, physical activity, and other problem behaviors*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16460300" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : 4. The use and misuse of performance-enhancing substances in sport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17024651" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Doping, drugs and drug abuse among adolescents in the State of Thuringia (Germany): prevalence, knowledge and attitudes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347346" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Systematic review: the effects of growth hormone on athletic performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7684551" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1550219" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effect of growth hormone and resistance exercise on muscle growth in young men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15784718" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439575" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19141266" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Performance-enhancing drugs snare nonathletes, too.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155963" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Growth hormone in sport: beyond Beijing 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21175915" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Human growth hormone abuse in male weightlifters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17955018" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Technology insight: detecting growth hormone abuse in athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17339122" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Detection of growth hormone abuse in sport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18381573" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pharmacodynamics of growth hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20203018" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pharmacology. Growth hormone test finally nabs first doper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34726230" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23934394" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Insulin-like growth factor-I (IGF-I) misuse in athletes and potential methods for detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9613908" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Insulin use by bodybuilders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18362898" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Erythropoiesis-stimulating agents and other methods to enhance oxygen transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18500377" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Drugs in sport: a scientist-athlete's perspective: from ambition to neurochemistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981937" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Total hemoglobin mass--a new parameter to detect blood doping?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17692836" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Possible origins of undetectable EPO in urine samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18295088" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Enhancement drugs and the athlete.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21988933" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Hemoglobin mass and biological passport for the detection of autologous blood doping.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
